CD274 and gastric cancer: Therefore, on the basis of our results showing locally advanced GC has a similar frequency of PD-L1 expression as late-stage GC, we designed a clinical trial to investigate the safety and effectivity of neoadjuvant immunotherapy for locally advanced GC (NCT04744649).